Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TNFRSF1A | P19438 | 18/20 | 0.62 |
| ▸ | ERN1 | O75460 | 1/20 | 0.51 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.45 |
| ▸ | NPC1 | O15118 | 1/20 | 0.45 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.45 |
| ▸ | TP53 | P04637 | 1/20 | 0.45 |
| ▸ | HPGD | P15428 | 1/20 | 0.45 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.45 |
| ▸ | RAB9A | P51151 | 1/20 | 0.45 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6095278 | 1.00 | TNFRSF1A (0.62) | TNFRSF1AERN1KDM4ENPC1ALDH1A1 | |
| SCHEMBL5960661 | 0.82 | ERN1 (0.68) | TNFRSF1AERN1 | |
| SCHEMBL27864586 | 0.78 | ALDH1A1 (0.66) | TNFRSF1AERN1KDM4ENPC1ALDH1A1 | |
| SCHEMBL5574892 | 0.77 | TNFRSF1A (1.00) | TNFRSF1AALDH1A1TP53HPGDMAPK1 | |
| SCHEMBL5574895 | 0.77 | TNFRSF1A (1.00) | TNFRSF1AALDH1A1TP53HPGDMAPK1 | |
| SCHEMBL5574947 | 0.76 | TNFRSF1A (1.00) | TNFRSF1A | |
| SCHEMBL5574946 | 0.76 | TNFRSF1A (1.00) | TNFRSF1A | |
| SCHEMBL8468558 | 0.76 | ERN1 (0.60) | TNFRSF1AERN1 | |
| SCHEMBL6040662 | 0.76 | TNFRSF1A (0.87) | TNFRSF1A | |
| SCHEMBL5571669 | 0.76 | TNFRSF1A (1.00) | TNFRSF1A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20060063828-A1 | 1,2-Bis-(substituted-phenyl)-2-propen-1-ones and pharmaceutical compositions thereof | ATHEROGENICS, INC. | 2006-03-23 | — | — | US | disclosed |
| WO-2006004903-A2 | 1,2-BIS-(SUBSTITUTED-PHENYL)-2-PROPEN-1-ONES AND PHARMACEUTICAL COMPOSITIONS THEREOF | ATHEROGENICS, INC. (US) | 2006-01-12 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060063828-A1 | 1,2-Bis-(substituted-phenyl)-2-propen-1-ones and pharmaceutical compositions thereof | ABCB11, CEL, CYP46A1 | TNFRSF1A 4880/4885ERN1 2367/4885KDM4E 1931/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.